New drug regimens under evaluation
| Trial | Drugs | Purpose | Status | Trial ID# |
| ReDEFINe | RIF (HD) | Assess high-dose RIF on treatment outcomes and duration in TB meningitis | Phase II | NCT02169882 |
| TB-PRACTECAL | BDQ, Pa, LZD, MFX, CFZ | Assess 6 months of regimen for MDR-TB | Phase III (data Analysis) | NCT02589782 |
| Stream stage 2 | CFZ, ETM, MFX, PZA, INH, Kan, Pro, BDQ, LFX | Varying combinations at differing durations for RR-TB and MDR-TB | Phase III | NCT02409290 |
| SimpliciTB | BDQ, Pa, MFX, PZA | 4 months for DS-TB 6 months for MDR-TB | Phase III | NCT03338621 |
| Truncate-TB | BDQ, RFP, LZD, MFX | 2 months for DS TB | Phase III | NCT03474198 |
| TBTC study 31 | RFP, INH, ETM, PZA, MFX | Evaluate 4 months treatment for DS-TB | Phase III | NCT02410772 |
| endTB | BDQ, DLM, LZD, MFX, PZA, LFX, CFZ | 47 weeks treatment with combinations of 5 drugs for MDR-TB | Phase III | NCT02754765 |
| RIFASHORT | RIF (HD) | Evaluate 4 months of RIF (HD) | Phase III | NCT02581527 |
| NEXT trial | LZD, BDQ, PZA, ETH or INH (HD) | Evaluate efficacy of ETH or INH (HD) with 6–9 months treatment for MDR-TB | Phase III (data Analysis) | NCT02454205 |
| ZeNix | Pa, LZD, BDQ, Pl | Evaluate 26 weeks treatment | Phase III | NCT03086486 |
| DELIBERATE | BDQ, DLM | Evaluate safety in MDR-TB | Phase III | NCT02583048 |
| BEAT TB | BDQ, DLM, LZD, LFX, CFZ | Evaluate safety and efficacy of 6 months treatment for RR-TB | Phase III | NCT04062201 |
HD: high dose; RIF: rifampicin; INH: isoniazid; RFP: rifapentine; ETM: ethambutol; PZA: pyrazinamide; MFX: moxifloxacin; LFX: levofloxacin; LZD: linezolid; ETH: ethionamide; BDQ: bedaquiline; DLM: delamanid; Pa: pretomanid; CFZ: clofazamine; Kan: kanamycin; Pro: prothionamide; Pl: Placebo. #: ClinicalTrials.gov identifier. Information from [1, 104].